Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Abandoned drugs
Elzasonan
Другие языки:

    Elzasonan

    Подписчиков: 0, рейтинг: 0
    Elzasonan
    Elzasonan structure.svg
    Clinical data
    Routes of
    administration    		 Oral
    ATC code
    • none
    Legal status
    Legal status
    • In general: uncontrolled
    Identifiers
    • 4-(3,4-dichlorophenyl)-2-[2-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3-one
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    Chemical and physical data
    Formula C22H23Cl2N3OS
    Molar mass 448.41 g·mol−1
    3D model (JSmol)
    • Clc4c(Cl)cc(N1C(=O)C(\SCC1)=C\c3ccccc3N2CCN(C)CC2)cc4
    • InChI=1S/C22H23Cl2N3OS/c1-25-8-10-26(11-9-25)20-5-3-2-4-16(20)14-21-22(28)27(12-13-29-21)17-6-7-18(23)19(24)15-17/h2-7,14-15H,8-13H2,1H3/b21-14-
    • Key:LHYMPSWMHXUWSK-STZFKDTASA-N
      (verify)

    Elzasonan (CP-448,187) is a selective 5-HT1B and 5-HT1D receptor antagonist that was under development by Pfizer for the treatment of depression but was discontinued, possibly due to poor efficacy. By preferentially blocking 5-HT1B and 5-HT1Dautoreceptors, elzasonan is thought to enhance serotonergic innervations originating from the raphe nucleus, thereby improving signaling to limbic regions like the hippocampus and prefrontal cortex and ultimately resulting in antidepressant effects.

    See also


    Новое сообщение